Assessing Plasmin Generation in Health and Disease
Fibrinolysis is an important process in hemostasis responsible for dissolving the clot during wound healing. Plasmin is a central enzyme in this process via its capacity to cleave fibrin. The kinetics of plasmin generation (PG) and inhibition during fibrinolysis have been poorly understood until the...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/5/2758 |
| _version_ | 1797542064086319104 |
|---|---|
| author | Adam Miszta Dana Huskens Demy Donkervoort Molly J. M. Roberts Alisa S. Wolberg Bas de Laat |
| author_facet | Adam Miszta Dana Huskens Demy Donkervoort Molly J. M. Roberts Alisa S. Wolberg Bas de Laat |
| author_sort | Adam Miszta |
| collection | DOAJ |
| description | Fibrinolysis is an important process in hemostasis responsible for dissolving the clot during wound healing. Plasmin is a central enzyme in this process via its capacity to cleave fibrin. The kinetics of plasmin generation (PG) and inhibition during fibrinolysis have been poorly understood until the recent development of assays to quantify these metrics. The assessment of plasmin kinetics allows for the identification of fibrinolytic dysfunction and better understanding of the relationships between abnormal fibrin dissolution and disease pathogenesis. Additionally, direct measurement of the inhibition of PG by antifibrinolytic medications, such as tranexamic acid, can be a useful tool to assess the risks and effectiveness of antifibrinolytic therapy in hemorrhagic diseases. This review provides an overview of available PG assays to directly measure the kinetics of plasmin formation and inhibition in human and mouse plasmas and focuses on their applications in defining the role of plasmin in diseases, including angioedema, hemophilia, rare bleeding disorders, COVID-19, or diet-induced obesity. Moreover, this review introduces the PG assay as a promising clinical and research method to monitor antifibrinolytic medications and screen for genetic or acquired fibrinolytic disorders. |
| first_indexed | 2024-03-10T13:25:21Z |
| format | Article |
| id | doaj.art-9c71367284e142ea9b01c799b673b786 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T13:25:21Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-9c71367284e142ea9b01c799b673b7862023-11-21T09:43:19ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-03-01225275810.3390/ijms22052758Assessing Plasmin Generation in Health and DiseaseAdam Miszta0Dana Huskens1Demy Donkervoort2Molly J. M. Roberts3Alisa S. Wolberg4Bas de Laat5Synapse Research Institute, 6217 KD Maastricht, The NetherlandsSynapse Research Institute, 6217 KD Maastricht, The NetherlandsSynapse Research Institute, 6217 KD Maastricht, The NetherlandsSynapse Research Institute, 6217 KD Maastricht, The NetherlandsDepartment of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USASynapse Research Institute, 6217 KD Maastricht, The NetherlandsFibrinolysis is an important process in hemostasis responsible for dissolving the clot during wound healing. Plasmin is a central enzyme in this process via its capacity to cleave fibrin. The kinetics of plasmin generation (PG) and inhibition during fibrinolysis have been poorly understood until the recent development of assays to quantify these metrics. The assessment of plasmin kinetics allows for the identification of fibrinolytic dysfunction and better understanding of the relationships between abnormal fibrin dissolution and disease pathogenesis. Additionally, direct measurement of the inhibition of PG by antifibrinolytic medications, such as tranexamic acid, can be a useful tool to assess the risks and effectiveness of antifibrinolytic therapy in hemorrhagic diseases. This review provides an overview of available PG assays to directly measure the kinetics of plasmin formation and inhibition in human and mouse plasmas and focuses on their applications in defining the role of plasmin in diseases, including angioedema, hemophilia, rare bleeding disorders, COVID-19, or diet-induced obesity. Moreover, this review introduces the PG assay as a promising clinical and research method to monitor antifibrinolytic medications and screen for genetic or acquired fibrinolytic disorders.https://www.mdpi.com/1422-0067/22/5/2758plasminplasmin generationfibrinolysis |
| spellingShingle | Adam Miszta Dana Huskens Demy Donkervoort Molly J. M. Roberts Alisa S. Wolberg Bas de Laat Assessing Plasmin Generation in Health and Disease International Journal of Molecular Sciences plasmin plasmin generation fibrinolysis |
| title | Assessing Plasmin Generation in Health and Disease |
| title_full | Assessing Plasmin Generation in Health and Disease |
| title_fullStr | Assessing Plasmin Generation in Health and Disease |
| title_full_unstemmed | Assessing Plasmin Generation in Health and Disease |
| title_short | Assessing Plasmin Generation in Health and Disease |
| title_sort | assessing plasmin generation in health and disease |
| topic | plasmin plasmin generation fibrinolysis |
| url | https://www.mdpi.com/1422-0067/22/5/2758 |
| work_keys_str_mv | AT adammiszta assessingplasmingenerationinhealthanddisease AT danahuskens assessingplasmingenerationinhealthanddisease AT demydonkervoort assessingplasmingenerationinhealthanddisease AT mollyjmroberts assessingplasmingenerationinhealthanddisease AT alisaswolberg assessingplasmingenerationinhealthanddisease AT basdelaat assessingplasmingenerationinhealthanddisease |